


Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-20. (Canceled)

21. (Currently amended) A pharmaceutical composition comprising ~~a SMIP compound and a benzazole compound and~~ an antigen, wherein the ~~SMIP compound is a benzazole compound is~~ of formula (XXI):



wherein,

A is selected from the group consisting of -O-, -S-, -NH-, and -NR₈-;

W is selected from the group consisting of -CH₂-, -O-, -S-, -NH-, and -NR₈-;

R₇ is selected from the group consisting of carbocyclyl, unfused carbocyclylcarbocyclyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, unsubstituted heteroaryl, substituted fused arylheteroaryl, unsubstituted fused arylheteroaryl, substituted unfused arylaryl and unsubstituted unfused arylaryl;

R₈ is selected from the group consisting of substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; and,

R₈ is independently substituted or unsubstituted alkyl;

or a pharmaceutically acceptable salt, ester, or prodrug thereof;

wherein said composition elicits an immune response in a subject.

22-23. (Canceled)

24. (Currently amended) The pharmaceutical composition of claim 21 wherein the antigen is associated with a disease selected from the group consisting of ~~BCG~~, mycobacterial infection, cholera, plague, typhoid, hepatitis B ~~infection~~, influenza, ~~inactivated~~-polio, rabies, measles, mumps, rubella, ~~oral polio~~, yellow fever, tetanus, diphtheria, hemophilus influenzae b, ~~meningococcus~~ meningococcal infection, and ~~pneumococcus~~ pneumococcal infection.

25. (Canceled)

26. (Previously presented) The pharmaceutical composition according to claim 21 wherein the immune response is the cellular production of one or more cytokines.

27-29. (Canceled)

30. (Currently amended) The pharmaceutical composition of claim 21 wherein the SMIP benzazole compound is selected from the group consisting of:

N-methyl-4-[(2-[(2-(1-methylethyl)phenyl)amino]-1H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide;

N-methyl-4-[(1-methyl-2-[(3-[(trimethylsilyl)ethynyl]phenyl)amino]-1H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide;

N-methyl-4-[(1-methyl-2-[(2-(phenylcarbonyl)phenyl)amino]-1H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide;

4-[(2-[(4-butylphenyl)amino]-1,3-benzothiazol-5-yl)oxy]-N-methylpyridine-2-carboxamide;

N-methyl-4-[(1-methyl-2-[(6-pyrrolidin-1-ylpyridin-3-yl)amino]-1H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide;

4-[(2-[1,1'-bi(cyclohexyl)-2-ylamino]-1-methyl-1H-benzimidazol-5-yl)oxy]-N-methylpyridine-2-carboxamide;

4-[(2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl)oxy]-N-1,3-thiazol-2-ylpyridine-2-carboxamide;

4-[(1-methyl-2-[(2-(methyloxy)phenyl)amino]-1H-benzimidazol-5-yl)oxy]-N-[3-(methyloxy)propyl]pyridine-2-carboxamide; and,

4-[(2-[(4-ethylphenyl)amino]-1,3-benzoxazol-5-yl)oxy]-N-methylpyridine-2-carboxamide.

31-35. (Canceled)

36. (Previously presented) The pharmaceutical composition of claim 21, wherein the antigen is associated with influenza.

37. (Previously presented) The pharmaceutical composition of claim 21, wherein the antigen comprises haemagglutinin and/or neuraminidase surface protein.

38. (Previously presented) The pharmaceutical composition according to any one of claims 21, 24, 26, 36, or 37, further comprising an adjuvant.

39. (Currently amended) The pharmaceutical composition of claim 38, wherein the adjuvant is ~~MF59~~ an oil-in-water emulsion.